EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer

Shawn Noronha, Yue Liu, Gaga Geneti, Haojian Li, Xiaolin Wu, David Sun, Vaibhavi Gujar, Takashi Furusawa, Alexei Lobanov, Maggie Cam iD, Lipika R Pal, Nishanth U Nair und 15 weitere

Molecular Carcinogenesis · 2026-07 · 65 (7) · 874-887

DOI: 10.1002/mc.70122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 26.04.2026. Verfasst von Shawn Noronha und 26 weiteren Autor:innen. Beteiligte Einrichtung: Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Thyroid Carcinoma, Anaplastic, Drug Resistance, Neoplasm, Thyroid Neoplasms. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer. Despite recent advances in treating BRAFV600E‐driven ATC, therapy resistance remains a significant challenge, often resulting in disease progression and death. Leveraging a focused CRISPR/KO screen in parallel with a CRISPR/activation screen, both tailored on response to BRAFV600E inhibitor treatment, we identified TAZ (encoded by WWTR1 gene) deficiency as synthetically lethal with BRAF inhibitor in ATC. TAZ is overexpressed in ATC compared to well‐differentiated thyroid tumors. We demonstrate that TAZ‐deficient ATC cells display heightened sensitivity to BRAF inhibitors. Using gene essentiality score across cancer cell lines, we found that BRAFV600E‐driven cancers are highly sensitive to TAZ loss, unlike their counterparts with wild‐type BRAF and non‐BRAFV600E. Mechanistically, we demonstrate that dabrafenib triggers the Unfolded Protein Response (UPR) under ER stress and suppresses protein synthesis. TAZ loss represses the UPR, reverses the inhibition of protein synthesis, and triggers increased cell death by ferroptosis in dabrafenib‐treated ATC. Collectively, our findings unveil TAZ as a new target to overcome resistance to BRAF inhibitors in undifferentiated thyroid cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafThyroid Carcinoma, AnaplasticDrug Resistance, NeoplasmThyroid NeoplasmsProtein Kinase InhibitorsHumansCell Line, TumorTranscriptional Coactivator with PDZ-Binding Motif ProteinsImidazolesOximesUnfolded Protein ResponseGene Expression Regulation, NeoplasticCRISPR-Cas Systems

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanProtein Kinase InhibitorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsWWTR1 protein, humanImidazolesdabrafenibOximes

Autor:innen und Institutionen

  • Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, Texas, USA.
  • Laboratory Animal Sciences Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • NCI Genomics Technology, Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research/Frederick, Maryland, USA.
  • Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Maggie Cam, Jaydira Del Rivero, Myriem Boufraqech

Zitieren

APA

Noronha, S., Liu, Y., Geneti, G., Li, H., Wu, X., Sun, D., Gujar, V., Furusawa, T., Lobanov, A., Cam, M., Pal, L. R., Nair, N. U., Day, C. P., Ruppin, E., Ghosh, C., Hu, J., Ramamoorthy, B., Kumar, S., Andresson, T., …, & Boufraqech, M. (2026). CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer. Molecular Carcinogenesis, 65(7), 874-887. https://doi.org/10.1002/mc.70122

Vancouver

Noronha S, Liu Y, Geneti G, Li H, Wu X, Sun D, et al. CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer. Molecular Carcinogenesis. 2026;65(7):874-887. doi:10.1002/mc.70122

BibTeX
@article{Noronha2026,
  author = {Noronha, Shawn and Liu, Yue and Geneti, Gaga and Li, Haojian and Wu, Xiaolin and Sun, David and Gujar, Vaibhavi and Furusawa, Takashi and Lobanov, Alexei and Cam, Maggie and Pal, Lipika R and Nair, Nishanth U and Day, Chi-Ping and Ruppin, Eytan and Ghosh, Chandrayee and Hu, Jiangnan and Ramamoorthy, Bhavishya and Kumar, Suresh and Andresson, Thorkell and Chan, King and O'Neill, Maura and Chari, Raj and Pommier, Yves and Rivero, Jaydira Del and Weyemi, Urbain and Kebebew, Electron and Boufraqech, Myriem},
  title = {CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  volume = {65},
  number = {7},
  pages = {874--887},
  doi = {10.1002/mc.70122}
}
Kostenlos starten →